Linktu2021-03-19 17:01
$Zosano Pharma(ZSAN)$
于2021年1月29日完成了与美国食品和药物管理局(“ FDA”)神经内科II(“部门”)的A型会议,有关Qtrypta(佐米曲普坦透皮微针系统)505(b)的重新提交要求(2)于2020年10月20日收到完整答复信后的新药申请(“ NDA”)
公司计划进行另一项药代动力学研究,该研...查看全文
$Zosano Pharma Corporation(ZSAN)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2016-11-16 AccNo: 0001019056-16-001662 Size: 130 KB 网页链接
$Zosano Pharma Corporation(ZSAN)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2016-11-09 AccNo: 0001193125-16-764437 Size: 3 MB 网页链接
$Zosano Pharma Corporation(ZSAN)$ 8-K - Current report Filed: 2016-11-09 AccNo: 0001193125-16-764424 Size: 72 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Zosano Pharma Corporation(ZSAN)$ 8-K - Current report Filed: 2016-11-03 AccNo: 0001193125-16-758838 Size: 17 KBItem 5.07: Submission of Matters to a Vote of Security Holders 网页链接
$Zosano Pharma Corporation(ZSAN)$ CORRESP [Cover] - Correspondence Filed: 2016-09-21 AccNo: 0001193125-16-716001 Size: 8 KB 网页链接
$Zosano Pharma Corporation(ZSAN)$ UPLOAD [Cover] - SEC-generated letter Filed: 2016-09-21 AccNo: 0000000000-16-093854 Size: 155 KB 网页链接
$Zosano Pharma Corporation(ZSAN)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2016-10-17 AccNo: 0000919574-16-015902 Size: 110 KB 网页链接
$Zosano Pharma Corporation(ZSAN)$ 8-K - Current report Filed: 2016-10-14 AccNo: 0001193125-16-738674 Size: 14 KBItem 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 网页链接
$Zosano Pharma Corporation(ZSAN)$ DEF 14A - Other definitive proxy statements Filed: 2016-10-07 AccNo: 0001193125-16-733827 Size: 370 KB 网页链接
$Zosano Pharma Corporation(ZSAN)$ EFFECT - Notice of Effectiveness Filed: 2016-09-23 AccNo: 9999999995-16-005768 Size: 1 KB 网页链接